Ultralife price target raised to $14 from $13 at Benchmark

Benchmark raised the firm’s price target on Ultralife to $14 from $13 and keeps a Buy rating on the shares. The analyst sees the company’s harsh environment battery technology, new product portfolio and strategic management initiatives “all inflecting.” Ultralife’s organic growth is accelerating, the CEO’s strategic initiatives across efficiency and supply chain have turned a corner, and new product launches “offer substantial near-term upside optionality,” the analyst tells investors in a research note.